argenx SE ARGNF
Set alert
At close · Oct 30
- YTD
- +3.48%
- 1 year
- +14.53%
- Open
- 995.00
- Prev close
- 900.30
- Mkt cap
- 56.62B
- Vol
- 49
- Avg vol
- 7
- EPS
- 28.87
- P/E
- 31.18
More statistics
- Low
- 995.00
- High
- 995.00
News
1 week ago fool.com
argenx: 3 Key Takeaways for Long-Term Investors
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
1 month ago businesswire.com
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
2 months ago businesswire.com
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology…
3 months ago wsj.com
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
3 months ago reuters.com
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
3 months ago reuters.com
Argenx's Vyvgart sales jump in second quarter
Belgian-Dutch immunology company argenx said on Thursday global sales of its lead drug Vyvgart jumped in the second quarter of 2026 from a year earlier.
4 months ago investors.com
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
5 months ago seekingalpha.com
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
argenx SE (ARGX) Q1 2026 Earnings Call Transcript